CQCIL Stock Overview
Cipla Quality Chemical Industries Limited, a pharmaceutical manufacturing company, manufactures and delivers anti-retroviral, anti-malarial, and hepatitis B medicines.
Cipla Quality Chemical Industries Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||USh65.00|
|52 Week High||USh100.00|
|52 Week Low||USh65.00|
|1 Month Change||-7.14%|
|3 Month Change||-5.80%|
|1 Year Change||-31.58%|
|3 Year Change||-49.22%|
|5 Year Change||n/a|
|Change since IPO||-75.19%|
Recent News & Updates
|CQCIL||UG Pharmaceuticals||UG Market|
Return vs Industry: CQCIL exceeded the UG Pharmaceuticals industry which returned -34.6% over the past year.
Return vs Market: CQCIL underperformed the UG Market which returned -29% over the past year.
|CQCIL Average Weekly Movement||2.1%|
|Pharmaceuticals Industry Average Movement||4.1%|
|Market Average Movement||3.2%|
|10% most volatile stocks in UG Market||4.5%|
|10% least volatile stocks in UG Market||1.1%|
Stable Share Price: CQCIL is less volatile than 75% of UG stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: CQCIL's weekly volatility (2%) has been stable over the past year.
About the Company
Cipla Quality Chemical Industries Limited, a pharmaceutical manufacturing company, manufactures and delivers anti-retroviral, anti-malarial, and hepatitis B medicines. It offers Duovir-N; Lamivudine and Zidovudine; Efavir 60; Duomune; Nevirapine; Efavirenz, Lamivudine, and Tenofovir; and Dolutegravir, Lamivudine, and Tenofovir tablets for the treatment of HIV infection. The company also offers Lumartem/Lumet tablets for the treatment of malaria; and Texavir and Zentair for the treatment of Hepatitis B infection.
Cipla Quality Chemical Industries Fundamentals Summary
|CQCIL fundamental statistics|
Is CQCIL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CQCIL income statement (TTM)|
|Cost of Revenue||USh229.51b|
Last Reported Earnings
Mar 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-2.89|
|Net Profit Margin||-3.70%|
How did CQCIL perform over the long term?See historical performance and comparison
Is CQCIL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CQCIL?
Other financial metrics that can be useful for relative valuation.
|What is CQCIL's n/a Ratio?|
Price to Sales Ratio vs Peers
How does CQCIL's PS Ratio compare to its peers?
|CQCIL PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
CAN Cann Group
503 Lansen Pharmaceutical Holdings
APPH Apontis Pharma
CQCIL Cipla Quality Chemical Industries
Price-To-Sales vs Peers: CQCIL is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (3x).
Price to Earnings Ratio vs Industry
How does CQCIL's PE Ratio compare vs other companies in the African Pharmaceuticals Industry?
Price-To-Sales vs Industry: CQCIL is good value based on its Price-To-Sales Ratio (0.8x) compared to the African Pharmaceuticals industry average (0.8x)
Price to Sales Ratio vs Fair Ratio
What is CQCIL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||0.8x|
|Fair PS Ratio||n/a|
Price-To-Sales vs Fair Ratio: Insufficient data to calculate CQCIL's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of CQCIL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CQCIL (UGX65) is trading above our estimate of fair value (UGX41.71)
Significantly Below Fair Value: CQCIL is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Cipla Quality Chemical Industries forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cipla Quality Chemical Industries has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine Cipla Quality Chemical Industries's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
How has Cipla Quality Chemical Industries performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: CQCIL is currently unprofitable.
Growing Profit Margin: CQCIL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CQCIL's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CQCIL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CQCIL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (30.7%).
Return on Equity
High ROE: CQCIL has a negative Return on Equity (-7.77%), as it is currently unprofitable.
Discover strong past performing companies
How is Cipla Quality Chemical Industries's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: CQCIL's short term assets (UGX143.9B) exceed its short term liabilities (UGX65.8B).
Long Term Liabilities: CQCIL's short term assets (UGX143.9B) exceed its long term liabilities (UGX24.7B).
Debt to Equity History and Analysis
Debt Level: CQCIL's net debt to equity ratio (18.8%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if CQCIL's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: CQCIL's debt is well covered by operating cash flow (79.5%).
Interest Coverage: CQCIL's interest payments on its debt are not well covered by EBIT (1.5x coverage).
Discover healthy companies
What is Cipla Quality Chemical Industries's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Cipla Quality Chemical Industries Dividend Yield vs Market|
|Company (Cipla Quality Chemical Industries)||0%|
|Market Bottom 25% (UG)||5.6%|
|Market Top 25% (UG)||10.9%|
|Industry Average (Pharmaceuticals)||2.5%|
|Analyst forecast in 3 Years (Cipla Quality Chemical Industries)||n/a|
Notable Dividend: Unable to evaluate CQCIL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CQCIL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CQCIL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CQCIL's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: CQCIL is not paying a notable dividend for the UG market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CQCIL has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ajay Kumar Pal serves as Chief Executive Officer since February 2020 & Executive Director at Cipla Quality Chemical Industries Limited. Ajay Kumar Pal joined CiplaQCIL in February 2020.
Experienced Management: CQCIL's management team is seasoned and experienced (13.7 years average tenure).
Experienced Board: CQCIL's board of directors are considered experienced (4.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Cipla Quality Chemical Industries Limited's employee growth, exchange listings and data sources
- Name: Cipla Quality Chemical Industries Limited
- Ticker: CQCIL
- Exchange: UGSE
- Founded: 2005
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: USh237.374b
- Shares outstanding: 3.65b
- Website: https://www.ciplaqcil.co.ug
Number of Employees
- Cipla Quality Chemical Industries Limited
- Luzira Industrial Park
- Plot 1-7, 1st Ring Road
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CQCIL||UGSE (Uganda Stock Exchange)||Yes||Ordinary Shares||UG||UGX||Sep 2018|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/27 00:00|
|End of Day Share Price||2022/09/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.